Due to the severe shortage of drug, please refrain from using IVIG in the off-label unapproved settings. IVIG is used to provide passive immunity in susceptible individuals exposed to certain infectious diseases for which no vaccine is available for active immunization or when there is not time to stimulate antibody production. Despite the apparent promise of IVIG in the treatment of the off-label indications, the evidence available in the literature supports only a few conditions for which it has been administered. Based upon the fact that most of the data addressing off-label use is derived from uncontrolled case reports and open series rather than randomized, controlled trials, as well as the high cost associated with IVIG therapy, a consensus panel was named to provide unbiased information regarding the use of these agents. UHC consensus panel recommendations addressed interchangeability of the various agents, adverse effects, and valid off-label uses when standard approached have failed, become intolerable, or are contraindicated.
All IVIG products are interchangeable.
Use of IVIG outside of these indications is not recommended. Dosing of IVIG should be consistent with manufacturer's recommendations based on indication. Recommendations for off-label use of intravenously administered immunoglobulin preparations.